Introduction Objectives
• With the majority of the world's population, a large number of patients with rare diseases and relatively limited access to appropriate medicines compared with western countries, Asia represents a real opportunity for the commercialisation of orphan drugs • However, despite some countries implementing policy to facilitate this process, funding for orphan drugs remains challenging since healthcare budgets are primarily focused on essential medicines for the broader population
• To understand the current coverage policies for orphan drugs in China, Taiwan, Singapore and South Korea • To evaluate the impact policy has on the pricing and reimbursement status of orphan drugs and to define the drivers for access, in light of an increasing pressure on medical coverage for orphan conditions 
Methodology

Results
Conclusions
Low High
• While national policy exists in each of the markets studied (see figure 2) , there is no standard definition for orphan diseases across countries in Asia and specialist funding programs to provide coverage for drugs treating rare diseases are scarce • China, with its rapidly changing healthcare environment, may well take a lead in the provision of orphan drugs, with new policy currently being considered as part of proposed, future reforms • In South Korea, of the 27 western drugs analysed on the orphan drug list, only 7 are available for reimbursement via the National Health Insurance (Aubagio, Elaprase, Mepact, Replagel, Sinemet, Stribild and Torisel)
• We developed hypotheses on categories of access drivers where a grade of 1 to 3 was allocated to each driver based on its expected positive impact on access (see figure 1) • Drugs from western manufacturers with orphan designation in South Korea, according to the Ministry of Food and Drug Safety, and launched within the last 8 years were then graded and the results were comparatively analysed based on access status; 8 drugs were excluded from the analysis for not pertaining to true orphan status
Country
Healthcare system characteristics related to orphan drugs
China
• Since 2009, a fast-track approval process for drugs related to some rare diseases has been in effect with a separate regulation specifying that these drugs are eligible for reduced clinical trial requirements • Provincial coverage for orphan drugs remains low, however, Shanghai has recently implemented a specialist program for the coverage of 12 identified rare diseases providing funding of ~$32,200 per patient per year • Furthermore, at the national level, a "Bill of Rare Diseases" is currently under review including proposals for the establishment or reimbursement mechanisms and assistance networks for the treatment of rare diseases Singapore
• Singapore defines a rare disease as a life-threatening and severely debilitating illness affecting less than 20,000 people • The government allows importation of orphan drugs if they have been approved in other markets with a designated orphan status, even if they have not been evaluated or registered by the Ministry of Health • Additionally, orphan drugs are given top priority and fast-track status by the Ministry of Health during the registration process South Korea
• South Korea defines orphan diseases as those which affect less than 20,000 people in the country or those where there is currently no available treatment • The approval process is fast-tracked, taking between 6-9 months and, once approved, orphan drugs are awarded six years of marketing exclusivity • There are currently 170 drugs included on the orphan drug list, 35 of which are from western manufacturers with the rest comprising of locally produced generics and herbal medicines Taiwan
• Drugs meeting one of the following two criteria may apply for registration and market approval as orphan drugs:
o The major indications of the drug are for the prevention, diagnosis and treatment of a rare disease o Drugs that have been approved by other countries to have major indications for the prevention, diagnosis and treatment of a rare disease
• Patients that have been officially acknowledged as having a rare disease can apply to the BNHI for reimbursement of medical expenses • Reimbursement is usually capped at 70%, however, patients that qualify for low-income status can receive up to 100% for designated orphan drugs
• We conducted secondary analysis of approval and funding regulation for orphan drugs in China, Singapore, South Korea and Taiwan to gain an understanding of policies and incentives for manufacturers participating in this area • We identified drugs included on the orphan drug list in South Korea, chosen as a proxy market for other Asian countries, and reviewed their access status as per the National Health Insurance Corporation ( • With specific regulation for orphan drugs in each market and rapidly changing healthcare environments, particularly in China, public funding for orphan drugs is likely to continue to increase • China may become a leading market for orphan drugs in this region due to on-going healthcare reforms and specific reimbursement policy under consideration, potentially facilitating greater access to a large population; whether or not this will have a profound effect remains to be seen
• Most funding for rare diseases focuses on select, severe, life-threatening conditions where treatment options are often limited, with affordability in Asian markets remaining the major access barrier • Strategies to overcome affordability barriers in Asia, (e.g. patient access schemes), are not new to the region and are likely to continue to be utilised as a tool by international manufacturers for gaining market access and uptake in this region
